1e
19
1
49
2
2
18
1b
1d
18
37
79
1d
2 29
1d
25
Emily Y. Chu, M.D., Ph.D.
77
79
Associate Professor of Dermatology at the Hospital of the University of Pennsylvania
28
81
3
62
Member, Abramson Cancer Center Melanoma and Cutaneous Malignancies Program
8f
Co-director, Medical Oncodermatology Service, Hospital of the University of Pennsylvania
9d
Director, Dermatopathology Resident Education, Perelman School of Medicine, University of Pennsylvania
b5
Associate Director, Cutaneous Phenomics and Transcriptomics Core, Penn Skin Biology and Diseases Resource-Based Center (SBDRC)
9d
Director, Dermatopathology Fellowship Program, Perelman School of Medicine, University of Pennsylvania
11
Department: Dermatology
4
1
b
1d
46
Contact information
41
4
3
3
3
2
4
b
1f
41
2 Maloney Building
35 3600 Spruce Street
Philadelphia, PA 19104
26
35 3600 Spruce Street
Philadelphia, PA 19104
2e
Office: 215-662-6926
32 Fax: 215-662-7884
24
f
32 Fax: 215-662-7884
24
13
Education:
21 7 BS 5f (Molecular, Cellular, and Developmental Biology, with Distinction), summa cum laude) c
29 Yale University , 1999.
21 7 MS 3b (Molecular, Cellular, and Developmental Biology) c
28 Yale University, 1999.
21 8 PhD 27 (Cell and Molecular Biology) c
34 University of Pennsylvania , 2005.
21 7 MD 27 (Cell and Molecular Biology) c
33 University of Pennsylvania, 2006.
c
3
3
3
3
8a
Permanent link21 7 BS 5f (Molecular, Cellular, and Developmental Biology, with Distinction), summa cum laude) c
29 Yale University , 1999.
21 7 MS 3b (Molecular, Cellular, and Developmental Biology) c
28 Yale University, 1999.
21 8 PhD 27 (Cell and Molecular Biology) c
34 University of Pennsylvania , 2005.
21 7 MD 27 (Cell and Molecular Biology) c
33 University of Pennsylvania, 2006.
c
2 29
21
1e
1d
24
5e
26 Inherited skin tumor syndromes
3a Cutaneous reactions to targeted and immunotherapies
65
10 Melanoma
26 Inherited skin tumor syndromes
3a Cutaneous reactions to targeted and immunotherapies
1a 29
27
Description of Research Expertise
2f Molecular markers for melanoma26 Inherited skin tumor syndromes
3a Cutaneous reactions to targeted and immunotherapies
65
Description of Clinical Expertise
21 Dermatopathology10 Melanoma
26 Inherited skin tumor syndromes
3a Cutaneous reactions to targeted and immunotherapies
1a 29
23
87 Ma, S.A,, O’Day, C.P., Dentchev, T., Takeshita, J., Ridky. T.W., Seykora, J.T., Chu, E.Y. 2 70 : Expression of p15 in a spectrum of spitzoid melanocytic neoplasms. Journal of Cutaneous Pathology 2a 46(5): 310-316, 2019.
1b9 Parekh, V., Sobanko, J., Miller, C.J., Karakousis, G., Xu, W., Letrero, R., Elenitsas, R., Amaravadi, R., Schuchter, L.M., Nathanson, K., Xu, X., Elder, D.E., Wilson, M.A., Chu, E.Y. : NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions arising in advanced melanoma patients treated with vemurafenib. Journal of Cutaneous Pathology 46(3): 190-194, 2019.
14b Wang, L.L., Patel, G., Chiesa Fuxench, Z.C., McGettigan, S., Schuchter, L.M., Mitchell, T.C., Ming, M.E., Chu, E.Y. : Timing of onset of adverse cutaneous reactions associated with programmed cell death-1 inhibitors. JAMA Dermatology 154(9): 1057-1061, 2018.
159 Xu, M., Horrell, J., Snitow, M., Cui, J., Gochnauer, H., Syrett, C., Kallish, S., Seykora, J.T., Liu, F., Gaillard, D., Katz, J., Kaestner, K., Levin, B., Mansfield, C., Douglas, J., Cowart, B., Tordoff, M., Liu, F., Zhu, X., Barlow, L., Rubin, A., McGrath, J., Morrisey, E., Chu, E.Y., & Millar, S.E. c0 : WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation. Nature Communications 8(15397), 2017.
122 Marek Andrew J, Ming Michael E, Bartlett Edmund K, Karakousis Giorgos C, Chu Emily Y: Acral Lentiginous Histologic Subtype and Sentinel Lymph Node Positivity in Thin Melanoma. JAMA Dermatology 152(7): 836-7, Jul 2016.
173 Chu, E.Y., Wanat, K.A., Miller, C.J., Amaravadi, R.K., Fecher, L.A., Brose, M.S., McGettigan, S., Giles, L.R., Schuchter, L.M., Seykora, J.T., Rosenbach, M.: Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study. J Am Acad Dermatol 67(6): 1265-1272 2012.
112 Chu, E. Y., Freeman, A. F., Jing, H., Cowen, E. W., Davis, J., Su, H. C., Holland, S. M., Turner, M. L.: Cutaneous manifestations of DOCK8 deficiency syndrome. Arch Dermatol 148(1): 79-84, 2012.
15d Chu, E.Y., Hens, J., Andl, T., Kairo, A., Yamaguchi, T.P., Brisken, C., Glick, A., Wysolmerski, J.J., Millar, S.E.: Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis. Development 131(19): 4819-29, 2004.
103 Li, F., Ambrosini, G., Chu, E.Y., Plescia, J., Tognin, S., Marchisio, P.C., Altieri, D.C.: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396(6711): 580-4, 1998.
2c
7
1d
1f
Selected Publications
102 Nguyen, C.V., Gaddis, K.J., Stephens, M.R., Seykora, J.T., Chu, E.Y.: An intra-patient concordance study of mismatch repair protein immunohistochemical staining patterns in patients with Muir-Torre syndrome. 3d JAMA Dermatology 156(6): 1-5, 2020.87 Ma, S.A,, O’Day, C.P., Dentchev, T., Takeshita, J., Ridky. T.W., Seykora, J.T., Chu, E.Y. 2 70 : Expression of p15 in a spectrum of spitzoid melanocytic neoplasms. Journal of Cutaneous Pathology 2a 46(5): 310-316, 2019.
1b9 Parekh, V., Sobanko, J., Miller, C.J., Karakousis, G., Xu, W., Letrero, R., Elenitsas, R., Amaravadi, R., Schuchter, L.M., Nathanson, K., Xu, X., Elder, D.E., Wilson, M.A., Chu, E.Y. : NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions arising in advanced melanoma patients treated with vemurafenib. Journal of Cutaneous Pathology 46(3): 190-194, 2019.
14b Wang, L.L., Patel, G., Chiesa Fuxench, Z.C., McGettigan, S., Schuchter, L.M., Mitchell, T.C., Ming, M.E., Chu, E.Y. : Timing of onset of adverse cutaneous reactions associated with programmed cell death-1 inhibitors. JAMA Dermatology 154(9): 1057-1061, 2018.
159 Xu, M., Horrell, J., Snitow, M., Cui, J., Gochnauer, H., Syrett, C., Kallish, S., Seykora, J.T., Liu, F., Gaillard, D., Katz, J., Kaestner, K., Levin, B., Mansfield, C., Douglas, J., Cowart, B., Tordoff, M., Liu, F., Zhu, X., Barlow, L., Rubin, A., McGrath, J., Morrisey, E., Chu, E.Y., & Millar, S.E. c0 : WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation. Nature Communications 8(15397), 2017.
122 Marek Andrew J, Ming Michael E, Bartlett Edmund K, Karakousis Giorgos C, Chu Emily Y: Acral Lentiginous Histologic Subtype and Sentinel Lymph Node Positivity in Thin Melanoma. JAMA Dermatology 152(7): 836-7, Jul 2016.
173 Chu, E.Y., Wanat, K.A., Miller, C.J., Amaravadi, R.K., Fecher, L.A., Brose, M.S., McGettigan, S., Giles, L.R., Schuchter, L.M., Seykora, J.T., Rosenbach, M.: Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study. J Am Acad Dermatol 67(6): 1265-1272 2012.
112 Chu, E. Y., Freeman, A. F., Jing, H., Cowen, E. W., Davis, J., Su, H. C., Holland, S. M., Turner, M. L.: Cutaneous manifestations of DOCK8 deficiency syndrome. Arch Dermatol 148(1): 79-84, 2012.
15d Chu, E.Y., Hens, J., Andl, T., Kairo, A., Yamaguchi, T.P., Brisken, C., Glick, A., Wysolmerski, J.J., Millar, S.E.: Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis. Development 131(19): 4819-29, 2004.
103 Li, F., Ambrosini, G., Chu, E.Y., Plescia, J., Tognin, S., Marchisio, P.C., Altieri, D.C.: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396(6711): 580-4, 1998.
2c